Head-To-Head Survey: InterCure (NASDAQ:INCR) and Equillium (NASDAQ:EQ)

InterCure (NASDAQ:INCR) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Institutional and Insider Ownership

8.3% of InterCure shares are owned by institutional investors. Comparatively, 27.0% of Equillium shares are owned by institutional investors. 0.2% of InterCure shares are owned by company insiders. Comparatively, 30.3% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

InterCure has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Equillium has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for InterCure and Equillium, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	0	0	0	0	N/A
Equillium	0	0	1	0	3.00

Equillium has a consensus target price of $5.00, indicating a potential upside of 342.48%. Given Equillium’s higher possible upside, analysts plainly believe Equillium is more favorable than InterCure.

Profitability

This table compares InterCure and Equillium’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Equillium	-19.51%	-36.88%	-17.31%

Valuation & Earnings

This table compares InterCure and Equillium”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$272.67 million	0.29	-$16.83 million	$0.13	13.38
Equillium	$42.62 million	0.93	-$13.34 million	($0.36)	-3.14

Equillium has lower revenue, but higher earnings than InterCure. Equillium is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Summary

Equillium beats InterCure on 7 of the 13 factors compared between the two stocks.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

About Equillium

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.